// STATE LEGISLATION TRACKER

Illinois SB 3221: CONTROLLED SUB-XYLAZINE

⚖️ NEUTRAL for peptide users 👤 LOW user impact 📜 Status: Introduced

State: Illinois
Bill: SB 3221
Session: 104th
Filed: 2026-07-02
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Illinois SB3221 aims to classify xylazine as a Schedule III controlled substance, with specific exemptions for licensed veterinarians and other authorized professionals using it for animal or wildlife purposes. The bill also includes provisions for its use in euthanasia and chemical analysis. It does not directly address human use or the broader peptide ecosystem.

Key Points

Xylazine to be classified as Schedule III controlled substance.
Exemptions for veterinary and wildlife use.
Includes provisions for euthanasia and chemical analysis.
Does not directly impact human prescription peptides.

What to Watch For

Note Bill status: Referred to Assignments, indicating it's in the early stages of the legislative process.

Note Effective date is January 1, 2027, allowing time for adaptation to new regulations.

Concern Potential for increased regulatory burden on veterinary compounding and distribution of xylazine-containing products.

Where the Bill Stands

The bill has been introduced and referred to the Assignments committee for further consideration.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-10-05 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws